Compare iShares MSCI ACWI ETF (ACWI) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Danaher Corporation — how do they compare? iShares MSCI ACWI ETF trades at $161.26, while Danaher Corporation trades at $206.12 (market cap $147.18B). The key difference: Danaher Corporation pays a 0.76% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| ACWI | DHR | |
|---|---|---|
52-Week High | $161.44 | $242.05 |
52-Week Low | $132.04 | $161.91 |
Market Cap | — | $147.18B |
Sector | — | Health |
Enterprise Value | — | $169.39B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
